trending Market Intelligence /marketintelligence/en/news-insights/trending/xfetkrncnmghlqtas-hzeq2 content esgSubNav
In This List

Tocagen prices $30M common stock offering

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Tocagen prices $30M common stock offering

Tocagen Inc. priced its underwritten public offering of 3 million common shares at $10 apiece.

The clinical-stage, cancer-selective gene therapy company expects to raise gross proceeds of about $30 million from the offering, before deducting the underwriting discounts and commissions and other offering expenses.

Underwriters have a 30-day option to purchase up to an additional 450,000 common shares at the public offering price, less the underwriting discounts and commissions.

The offering is expected to close on or about Dec. 17, subject to customary closing conditions.

Citigroup and Leerink Partners are acting as joint book-running managers for the offering.